

Patent Docket No. **MPI00-437P1RM**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Glucksmann, Maria A. (as amended)
Application No.: 10/080,960 Group No.: 1652
Filed: October 19, 2001 Examiner: Saidha, Tekchand
For: 80090, 52874, 52880, 63497, AND 33425 METHODS AND COMPOSITIONS OF
HUMAN PROTEINS AND USES THEREOF

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the Restriction Requirement dated July 1, 2004, Applicants hereby elect Group 1, drawn to nucleic acid sequence SEQ ID NO:1 (cDNA) and SEQ ID NO:3 (coding), designated 80090, host cell and method of making polypeptide of SEQ ID NO:2 (claims 1-3 and 6; all in part), without prejudice to Applicant's right to pursue the non-elected subject matter in other applications.

Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups 2-40 in this or subsequent applications.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No. .

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 21, 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Applicants submit herewith a Preliminary Amendment canceling claims 1-24 and adding new claims 25-42. New claims 25-42 are directed to the subject matter of Group 1 and are therefore included in Applicants' election. Entry of the Preliminary Amendment prior to examination on the merits is respectfully requested.

It is believed this paper is being filed timely and no extensions of time are required. In the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.


Entry of the remarks made herein is respectfully requested.

July 21, 2004

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820